Transaction · 0001231919-26-000604

Ra Capital Management, L.P.

RA CAPITAL MANAGEMENT, L.P., DIR, reported a transaction classified as grant at Acumen Pharmaceuticals, Inc. involving 53250.000000 shares for an estimated $0.00. Reported holdings after the transaction were 53250.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
ABOSAcumen Pharmaceuticals, Inc.
Trade date
Jun 03, 2026
Filing date
Jun 05, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded53.2k$0.00 per share
Holdings after53.2kIndirect · See Footnotes
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ABOS price since this filing

Daily closing prices, with the filing date and available return windows
ABOS · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001231919-26-000604
Stock Option (Right to Buy)
Transaction date
Jun 03, 2026
Filed Jun 05, 2026, 09:12 PM · 2d delay
Shares
53,250 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
53,250 sh
Indirect · See Footnotes

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    Represents a restricted stock unit ("RSU") award to Laura Stoppel. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier o…

  2. F2

    RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed a…

  3. F3

    Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSUs and the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Stoppel is obligated to turn over to the…

  4. F4

    Held directly by the Fund.

  5. F5

    Held directly by the Nexus Fund II.

  6. F6

    Held directly by the Account.

  7. F7

    Represents the award of an option to Dr. Stoppel. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting…

Original filing · 0001231919-26-000604
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ABOS